ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain.
ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. It could disrupt binding between nNOS and NOS1AP using ex-vivo, in vitro, and purified recombinant systems. In vitro, ZLc002 reduced coimmunoprecipitation of full-length NOS1AP and nNOS in cultured neurons and HEK293T cells co-expressing full-length nNOS and NOS1AP[1].
[1] Lee WH, et al. Mol Pain. 2018 Jan-Dec;14:1744806918801224.
[2] Wan-Hung Lee. “ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability.” Molecular Pain 14 (2018): 1744806918801224.
